

**Anti-Tetranectin (human)
mouse monoclonal antibody**

Subclass: IgG₁/κ

PRODUCT NO.

HYB 130-13

Clone: 10E3

PRESENTATION

Preparation: Protein-A/G purified

Content: Available in 200 µL and 1 mL size. 1 mg/mL +/- 15%. See Certificate of Analysis for details.

Solvent: 0.01 M phosphate buffer, pH 7.4, containing 0.5 M NaCl and 15 mM sodium azide

Storage: 4-8°C without exposure to light. No precautions necessary during handling.

ANTIGEN

Tetranectin (TN) is a serum and tissue protein, a C-type lectin, which binds to Ca⁺⁺. It is a homotrimer of monomers each with a mass of 20 kDa, plasma or serum concentrations of TN are found to be approximately 10 mg/l (1,2,4). In vitro, TN can bind to kringle 4 of plasminogen and enhance the activation of plasminogen to plasmin, catalyzed by tissue plasminogen activator in the presence of poly-D-lysine (3). TN is best known as a prognostic marker in ovarian cancer.

IMMUNOGEN

Tetranectin purified from human citrate plasma (3) and coupled to PPD. Boosted before fusion with recombinant tetranectin produced in E. coli and adsorbed onto aluminum hydroxide gel

SPECIFICITY

HYB 130-13 is specific for amino acids 17-181 of human tetranectin monomer

EPI TOPE SPECIFICITY

Epitopespecificity is shared with HYB 130-11, as determined by inhibition ELISA (4).

REACTIVITY

HYB 130-13 reacts strongly with tetranectin. A strong reaction is seen in sandwich ELISA in combination with a polyclonal antibody against tetranectin (eg. DAKO A0371). In western blotting HYB 130-13 reacts strongly with TN monomer and not so well with TN trimer. In fresh frozen tissues of ovarian cancer, HYB 130-13 shows no staining for TN and no staining of paraffin-embedded, microwave treated tissues. Especially good as both capture and detecting antibody combined with a polyclonal antibody (A371) in sandwich ELISA (4).

CULTURE MEDIUM

Dulbecco's modified Eagle's medium with 10% fetal calf serum

FUSION PARTNER

X63-Ag8.653

IMMUNIZATION

Female CF1 x BALB/c mice immunized by intraperitoneal injection

APPLICATION

Method	Usability	References
ELISA	Yes	4,5
Immunoblotting	Yes	4
Immunohistochemistry	No	4

REFERENCES

- Holtet TL, Graversen JH, Clemmensen I, Thogersen HC, Etzerodt M (1997) Tetranectin, a trimeric plasminogen binding C-type lectin. *Protein Sci* 6:1-5.
- Nielsen BB, Kastrup JS, Rasmussen H, Holtet TL, Graversen JH, Etzerodt M, Thogersen HC, Larsen IK (1997) Crystal structure of tetranectin, a trimeric plasminogen-binding protein with an alpha-helical coiled coil. *FEBS Lett.* 412:388-96.
- Clemmensen I, Petersen LC, Kluff C (1986) Purification and characterization of a novel, oligomeric, plasminogen kringle 4 binding protein from human plasma: Tetranectin. *Eur J Biochem* 156:327-33.
- Hogdall CK, Christiansen M, Christensen L, Yazova AK, Koch C, Clemmensen I, Norgaard-Pedersen B (1997) Monoclonal antibodies against human tetranectin, epitope characterization and use in immunohistochemistry. *Clin Chim Acta* 258:159-177.
- Hogdall CK (1998) Human tetranectin: methodological and clinical studies. *APMIS Suppl* 86:1-31.
- Thougaard AV, Hogdall CK, Kjaer SK, Blaakaer J, Jaliashvili I, Christiansen M (1998) Determination of serum tetranectin: technical and clinical evaluation of three sandwich immunoassays. *Clin Chim Acta* 276:19-34.
- Thougaard AV, Jaliashvili I, Christiansen M (2001) Tetranectin-like protein in vertebrate serum: a comparative immunochemical analysis. *Comp Biochem Physiol B Biochem Mol Biol* 128:625-634.
- Westergaard UB, Andersen MH, Heegaard CW, Fedosov SN, Petersen TE (2003) Tetranectin binds hepatocyte

CONDITIONS

Unless otherwise marked, all products are for research use only. Not for use in diagnostic procedures. Not for use in human therapeutic applications. For in vitro use or further manufacture only. The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The foregoing is in lieu of all warranties, expressed or implied, including implied warranties of merchantability and fitness for a particular purpose. In no event shall BioPorto Diagnostics A/S be responsible for loss of profits or indirect consequential losses resulting from use of its products.